期刊文献+

常规剂量与大剂量阿托伐他汀在冠状动脉旁路移植术后疗效与安全性比较 被引量:2

下载PDF
导出
摘要 【目的】观察常规剂量与大剂量阿托伐他汙对冠状动脉旁路移植术(CABG)后血脂水平的彩响及副反应和近期桥血管通畅率的比较。【方法】选择本院接受CABG的患者138例,随机分为常规治疗组70例,强化治疗组68例,术后第一天起分别每日口服阿托伐他江20mg,40mg,观察一个月后血脂水平、肝功能、有无肌痛及三个月后乳内动脉直径及一年后桥血管的变化。【结果】强化治疗组低密度脂蛋白(LDL)与总胆固醇(TC)较常规治疗组低(P<0.05),丙氨酸氨基转移酶(ALT)在两组中均升高且强化组升高更明显(P<0.05).两组患者中均未出现肌痛现象。服药三个月后两组患者乳内动脉直径均无明显变化(P>0.05)。一年后强化洛疗组静脉血管桥通畅率更高(P<0.05)。【结论】CABG术后使用较大剂量他汀能强化降低血脂水平,提高了近期静脉桥血管的通畅性,大剂量他汀在CABG术后使用时增加了肝功能异帯的发生水平,需监测肝功能变化避免肝毒性的发生。
出处 《医学临床研究》 CAS 2020年第1期123-125,共3页 Journal of Clinical Research
  • 相关文献

参考文献2

二级参考文献43

  • 1潘殿柱,李永春.阿托伐他汀对低氧大鼠肺血管重建的影响[J].中国全科医学,2005,8(14):1149-1151. 被引量:10
  • 2Trion A,de MaatM,Jukema W,et al.Anti-atherosclerotic effect of amlodipine,alone and in combination with atorvastatin,in APOE * 3-Leiden/hCRP transgenic mice[J].J Canliovasc Pharmacol,2006,47:89-95.
  • 3Nissen SE,Tuzcu EM,Schoenhagen P,et al.Effect of intensive com-pared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:A randomized controlled trial[J].JAMA,2004,29:1071-1080.
  • 4Mason RP,Walter MF,Day CA,et al.Active metabolite of atorvasta-tin inhibits membrane cholesterol domain formation by an antioxidant mechanism[J].J Biol Chem,2006,281:9337-934S.
  • 5Baigent C,Keech A,Kearney PM.Efficacy and safety of cholesterol-lowering treatment:prospective raeta-analysis of data from 90,056participants in 14 randomised trials of statins[J].Lancet,2005,366:1267-1278.
  • 6Ma QL,Mo L,Yang TL,et al.Effecf of different doses of atorvastatin on adhesion molecules of the patients undergoing percutaneous coronary intervention[J].Zhong Nan Da Xue Xue Bao Yi Xue Ban,2006,31:914 -916.
  • 7Bonetti PO,Lerman LO,Napoli C,et al.Statin effects beyond lipid lowering-are they clinically relevant[J].Eur Heart J,2003,24:225-248.
  • 8Tousoulis D,Antoniades C,Katsi V,et al.The impact of early ad-ministration of low-dose atorvastatin treatment on inflammatory process,in patients with unstable angina and low cholesterol level[J].Int J Cardiol,2006,109:48-52.
  • 9Pearson TA.Mensah GA,Alexander RW,et al.Markers of inflam-mation and cardiovascular disease application to clinical and public health practice:a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association[J].Circulation,2003,107:499-512.
  • 10Llevadot J,Murasawa S,Kureishi Y,et al.HMG-CoA reductase in-hibitor mobilizes bone marrow-derived endothelial progenitor cells[J].J Clin Invest,2001,108:399-405.

共引文献80

同被引文献28

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部